What Is a Normal Anti-Müllerian Hormone Level in Pregnancy?

What Is a Normal Anti-Müllerian Hormone Level in Pregnancy?

AMH levels in a healthy pregnancy typically fall to less than 1.0 ng/mL — often near or below standard 'low' thresholds used in fertility workups — because the ovaries suppress follicle activity once conception occurs. This is expected and physiologically normal. The main caveat: AMH is not a meaningful pregnancy monitoring marker; it was designed to assess ovarian reserve before conception. The exception is women with granulosa cell tumors, where AMH is actively tracked throughout pregnancy as a tumor marker.

---

What AMH Actually Measures — and Why Pregnancy Changes Everything

Anti-Müllerian hormone is a glycoprotein produced by granulosa cells in small antral and pre-antral follicles. In non-pregnant reproductive-age women, serum AMH provides a reliable index of ovarian reserve — the number of remaining primordial follicles available for future recruitment (Broer et al., Human Reproduction Update 2014; PMID: 24516084).

That mechanism is the key to understanding why pregnancy alters the number so dramatically. Once a pregnancy is established, the pituitary suppresses gonadotropin secretion (particularly FSH), which in turn quiets follicular development across the ovary. Fewer actively developing follicles means fewer granulosa cells secreting AMH, so measured serum levels fall — sometimes by 40–60% compared to the woman's pre-conception baseline.

A landmark prospective cohort study by La Marca et al. (Reproductive BioMedicine Online 2010; PMID: 20638338) followed serum AMH across the three trimesters and confirmed a progressive decline from the first trimester onward, with the lowest values recorded in the third trimester. Importantly, levels partially recovered in the postpartum period, suggesting the suppression is functional rather than reflecting permanent follicle loss.

What this means clinically: If your AMH was measured during pregnancy and came back at 0.3–0.8 ng/mL, that number cannot be compared to a pre-pregnancy reference range. It is not a signal of diminished ovarian reserve in the long-term sense. Your provider should interpret it in context — or defer the ovarian reserve assessment until several months postpartum.

---

AMH Reference Ranges: Before vs. During Pregnancy

The table below contrasts the reference ranges used in fertility clinics (pre-pregnancy) with what published studies report as expected values during gestation.

These ranges are drawn from multiple prospective studies and should be treated as approximate population estimates, not universal cutoffs. Individual variation is substantial, and assay standardization across laboratories remains an ongoing clinical challenge (Pigny et al., European Journal of Endocrinology 2016; PMID: 27562873).

---

Why Low Pre-Pregnancy AMH Does Not Rule Out a Successful Pregnancy

One of the most persistent misconceptions in fertility medicine is that a low AMH equals an inability to conceive naturally. The evidence consistently challenges this framing.

A prospective cohort study by Steiner et al. published in JAMA (2017; PMID: 28934278) followed 750 women aged 30–44 trying to conceive without fertility treatment. Women with low AMH (< 0.7 ng/mL) did not have significantly lower odds of conceiving within six menstrual cycles compared to women with normal AMH, after adjusting for age. The authors concluded that AMH was not a useful predictor of natural fecundability in this population.

What AMH does predict well is the response to ovarian stimulation in assisted reproduction — the number of eggs retrieved per IVF cycle. That is a different clinical question from whether you can conceive on your own.

For women who have already conceived, a historically low pre-pregnancy AMH is not an established predictor of miscarriage risk, preterm birth, or fetal growth restriction in the absence of other pathology. Ongoing pregnancy monitoring is guided by progesterone, hCG trajectory, and ultrasound — not by AMH.

If you've been tracking low omega-3 symptoms and daily dose thresholds or other nutrient biomarkers alongside your fertility labs, that integrative approach makes sense — but AMH is simply not a marker that needs active management once pregnancy is confirmed.

---

AMH During Pregnancy: When It Does Matter Clinically

There are specific clinical scenarios where AMH measurement during pregnancy carries genuine diagnostic weight.

1. Granulosa Cell Tumors (GCTs)

Granulosa cell tumors of the ovary are a rare but important cause of markedly elevated AMH in pregnant and non-pregnant women alike. In GCT surveillance, AMH functions as a sensitive tumor marker — rising levels during pregnancy monitoring signal disease recurrence or progression and warrant urgent investigation (Mom et al., International Journal of Gynecological Cancer 2014).

2. Polycystic Ovary Syndrome (PCOS) and Pregnancy Complications

Women with PCOS often enter pregnancy with elevated AMH (sometimes > 5–8 ng/mL before conception). Several studies have explored whether persistently elevated AMH during early pregnancy associates with adverse outcomes, though the literature remains inconclusive. Current guidelines do not support routine AMH testing during pregnancy for PCOS monitoring.

3. Fetal Sex and AMH in Obstetric Research

Male fetuses produce AMH from their Sertoli cells — this is the hormone responsible for Müllerian duct regression in male embryogenesis. Maternal serum AMH is predominantly of ovarian granulosa cell origin, but researchers have explored whether fetal sex influences maternal AMH trajectory. Evidence to date suggests the effect, if any, is too small to affect clinical interpretation.

---

Homocysteine, Folate, and Other Pregnancy Biomarkers That Do Require Active Monitoring

Unlike AMH, several biomarkers actively shift during pregnancy in ways that carry direct clinical consequences and require monitoring:

• Folate — critical for neural tube development; status is monitored and supplemented throughout the first trimester and often beyond. Understanding what a normal folate level looks like in pregnancy helps contextualize your results alongside AMH in a full panel.
• Homocysteine — elevated levels associate with placental dysfunction and preeclampsia risk. Normal homocysteine ranges in pregnancy differ meaningfully from standard adult reference intervals.
• Magnesium — deficiency during pregnancy links to preterm labor and hypertensive disorders. Reviewing normal magnesium levels in pregnancy alongside your electrolyte panel gives a more complete nutritional picture.
• Zinc — essential for immune function and fetal development; what constitutes a normal zinc level in pregnancy is a commonly overlooked part of prenatal bloodwork.

AMH does not belong on this list. It is a retrospective window into ovarian history — useful before conception, not a dial to monitor once pregnant.

---

Postpartum AMH Recovery: What the Research Shows

For women concerned about their long-term ovarian reserve after pregnancy, the reassuring finding is that AMH levels generally recover toward pre-pregnancy baselines within three to twelve months postpartum, depending on breastfeeding status.

Breastfeeding extends hypothalamic-pituitary suppression via prolactin, which means follicular activity — and therefore AMH production — may remain blunted longer in lactating women. A study by Hale et al. (Fertility and Sterility 2007; PMID: 17126339) documented that AMH remained significantly suppressed in breastfeeding women at six months postpartum compared to formula-feeding controls, underscoring why a postpartum AMH drawn while nursing may still underestimate true ovarian reserve.

Clinical guidance: If you want an accurate ovarian reserve assessment after pregnancy, ideally wait until at least two to three regular menstrual cycles have returned. This gives the hypothalamic-pituitary-ovarian axis time to normalize and provides a more stable AMH reading.

---

How AMH Interacts With Other Hormonal Systems

AMH does not function in isolation. Its production is influenced by vitamin D status, thyroid function, and insulin sensitivity — all systems that also shift meaningfully during pregnancy.

Vitamin D and AMH: Several observational studies report a positive correlation between 25-hydroxyvitamin D levels and serum AMH in women of reproductive age (Dennis et al., Journal of Clinical Endocrinology & Metabolism 2012; PMID: 22170715). Whether correcting vitamin D deficiency improves AMH is debated, but the relationship underscores that AMH is not purely a fixed genetic read-out — it is influenced by modifiable physiological factors.

Thyroid function: Hypothyroidism can suppress AMH through its effects on follicular development. Women with subclinical hypothyroidism and low AMH sometimes see modest AMH improvement with thyroid hormone optimization, though evidence for causality remains preliminary.

Insulin resistance and PCOS: In hyperandrogenic PCOS, elevated insulin drives theca cell androgen production, which in turn stimulates granulosa cells — raising AMH above normal. This is why AMH is sometimes used alongside ultrasound antral follicle count as a PCOS diagnostic criterion.

---

What This Means for Your Formula

AMH itself is not a supplementable biomarker — no capsule raises or preserves ovarian reserve in a clinically proven way, and any claim to the contrary should be viewed with skepticism. That said, several physiological systems that interact with AMH and ovarian health do respond to targeted nutritional support.

Vitamin D3 + K2 (MK-7): Given the observed correlation between vitamin D status and AMH, maintaining adequate 25-OH-D levels is a reasonable evidence-informed goal. Ones formulas can include vitamin D3 paired with MK-7 to support calcium handling and immune function during preconception and pregnancy phases.

Zinc: Zinc plays a direct role in folliculogenesis and oocyte maturation. Clinical studies show that zinc deficiency impairs granulosa cell function and can reduce egg quality (Garner et al., Biology of Reproduction 2021). Ones includes zinc at doses calibrated to an individual's lab-confirmed status, avoiding both deficiency and excess — both of which can impair reproductive function.

Omega-3 (EPA/DHA): Polyunsaturated fatty acids support granulosa cell membrane integrity and reduce systemic inflammation, which can impair follicular microenvironment quality. Ones formulas that include Omega-3 are dosed to clinical ranges based on the user's baseline omega-3 index, not a generic one-size recommendation.

None of these ingredients directly raises AMH, and Ones does not make that claim. What they do is support the broader hormonal and cellular environment in which follicular health operates — a meaningful distinction for women optimizing preconception health based on actual lab data rather than guesswork.

---

Key Takeaways

• AMH falls significantly during pregnancy — often by 40–60% from pre-conception baseline — due to gonadotropin suppression and reduced follicular activity. A low AMH reading in pregnancy does not indicate diminished long-term ovarian reserve.
• Normal in-pregnancy AMH ranges from approximately 0.1–2.0 ng/mL depending on trimester; these values cannot be compared to standard fertility clinic reference ranges without context.
• Pre-pregnancy AMH does not reliably predict natural conception ability. The 2017 Steiner et al. JAMA study found no significant difference in conception rates between women with low versus normal AMH trying to conceive naturally.
• AMH monitoring during pregnancy is only clinically indicated in granulosa cell tumor surveillance and certain oncological contexts — not for routine prenatal care.
• Postpartum AMH recovery typically occurs within 3–12 months; breastfeeding delays recovery due to sustained prolactin-mediated suppression.
• Biomarkers that genuinely require active pregnancy monitoring — folate, homocysteine, magnesium, zinc — are distinct from AMH and carry direct clinical action thresholds.